Product Information

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB is a generic product labeled by Sandoz Inc., priced at $0.6167 per EA under NDC 00781564101. Its NADAC has been published 596 times since Aug 20, 2014.

FDA first approved this application on Jun 11, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB

Carbidopa, Levodopa, and Entacapone
$0.6167per EA

Strength

31.25; 200; 125 mg/1; mg/1; mg/1

Manufacturer

Sandoz Inc.

NDC

00781564101

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Authorized Generic (NDA)

FDA Application

NDA021485

FDA Approved

6/11/2003

TE Code

AB

On Market Since

6/18/2014

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid
Catechol O-Methyltransferase Inhibitors
Catechol-O-Methyltransferase Inhibitor

Price Statistics

The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has been published 596 times since Aug 20, 2014, and over the history we have for it it has declined 77.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6167 per EA
All-time high$2.6761 (Sep 10, 2014)
All-time low$0.6167 (Aug 19, 2026)
52-week high$0.7823
52-week low$0.6167
Median price$1.0516
Average price$1.2782
Largest weekly change+38.2% (Oct 19, 2016)
Weeks tracked596
Tracking sinceAug 20, 2014

Price History

1W

-0.2%

1M

-0.2%

3M

-8.1%

6M

-18.8%

1Y

-14.4%

3Y

-16.8%

5Y

-32.4%

All

-77.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Carbidopa, Levodopa, and Entacapone market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB, manufactured by Sandoz Inc., is $0.6167 per EA (NDC 00781564101), effective Aug 19, 2026.

How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB changed over time?

Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has declined 77.0%. It has been tracked across 596 weekly CMS publications since Aug 20, 2014.

What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

Since Aug 20, 2014, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB has ranged from a low of $0.6167 (Aug 19, 2026) to a high of $2.6761 (Sep 10, 2014), with a median of $1.0516 per EA.

Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB?

CARBIDOPA-LEVODOPA-ENTACAPONE 31.25-125-200 MG TAB (NDC 00781564101) is labeled by Sandoz Inc., and CMS classifies it as a generic product.